Anemia of Chronic Kidney Disease Clinical Trial
Official title:
Effect of Pentoxifylline Administration on Hemoglobin Level of Hemodialysis Patients
Our study investigated the effect of using a known drug used in intermittent claudication (named pentoxifylline) as an adjuvant to erythropoietin stimulating agents to improve anemia of hemodialysis patients.
Fifty out of 57 hemodialysis anemic patients were finally included. They were assigned to two
groups of equal numbers. Oral Pentoxifylline 400mg once daily was added to the treatment
group which was compared to the control group over a six months period regarding hemoglobin,
hematocrit, serum albumin and CRP.
Inclusion criteria: (Patients with ESRD on HD who have hemoglobin <11 g/dl, taking
Erythropoietin alfa 4000 -12000 I.U/wk and having a urea reduction ratio >65%.). There were
57 patients who met the inclusion criteria out of 158 patients.
Exclusion criteria: Iron deficiency anemia with transferrin saturation <30%, intact
PTH>300pg/ml, vitamin B12 or folate deficiency (evidenced by macrocytosis), history of
intolerance to pentoxifylline or other xanthine derivatives, recent retinal or cerebral
hemorrhage or active peptic ulcer disease, pregnancy or breastfeeding, presence of systemic
hematological disease or known hemoglobinopathy, major surgery, infection, acute myocardial
infarction, or malignancy within the last three months and patients who refused to
participate in the study.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03325621 -
Phase 2a Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT02198495 -
Comparison Study of Two Iron Compounds for Treatment of Anemia in Hemodialysis Patients
|
Phase 4 | |
| Suspended |
NCT03193073 -
Anemia Correction and Fibroblast Growth Factor 23 Levels in Chronic Kidney Disease , and Renal Transplant Patient
|
N/A | |
| Completed |
NCT02581124 -
Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease
|
Phase 1 | |
| Completed |
NCT02268994 -
KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD
|
Phase 3 | |
| Completed |
NCT04543812 -
PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKD
|
Phase 3 | |
| Recruiting |
NCT05900635 -
Effect of Adding Lactoferrin on Oral Iron on Anemia in Chronic Kidney Disease Patients
|
Phase 4 | |
| Completed |
NCT04667533 -
Desidustat in the Treatment of Chemotherapy Induced Anemia
|
Phase 1 | |
| Completed |
NCT02787824 -
Periodic Versus Continuous IV Iron Supplementation in HD Patients
|
Phase 4 | |
| Completed |
NCT03431623 -
CKD-11101 Phase 3 SC Study
|
Phase 3 | |
| Completed |
NCT01971164 -
Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease
|
Phase 1 | |
| Recruiting |
NCT01532349 -
Vitamin D as a Modifier of Serum Hepcidin in Children With Chronic Kidney Disease
|
Phase 2 | |
| Completed |
NCT05698420 -
Investigation of the Effects of Medium Cut-off Dialyzers Versus High-Flux Dialyzers on Clinical and Laboratory Parameters of Prevalent Hemodialysis Patients
|
||
| Completed |
NCT03427801 -
Effect of Erythropoiesis-Stimulating Agent Therapy in Patients Receiving Palliative Care of Chronic Kidney Disease
|
||
| Recruiting |
NCT03521713 -
To Evaluate the Efficacy, Safety, and Immunogenicity of Subcutaneous Eporon Versus Epoetin Alfa (Eprex)
|
Phase 3 | |
| Active, not recruiting |
NCT02754167 -
Phase Ib Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT02805244 -
Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis
|
Phase 1 | |
| Completed |
NCT03428594 -
CKD-11101 Phase 3 IV Study in Patients Who Had Renal Anemia Receiving Hemodialysis
|
Phase 3 | |
| Not yet recruiting |
NCT06352138 -
Comparative Study of Two Recombinant Human Erythropoietin Products on Chronic Kidney Disease Patients
|
Phase 3 | |
| Suspended |
NCT05082584 -
Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents
|
Phase 3 |